Talat Imran - Feb 3, 2022 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Chief Executive Officer, Director
Signature
/s/ Josh Seidenfeld, Attorney-in-Fact for Talat Imran
Stock symbol
RANI
Transactions as of
Feb 3, 2022
Transactions value $
$0
Form type
4
Date filed
2/7/2022, 08:52 PM
Previous filing
Sep 13, 2021
Next filing
Mar 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RANI Class A Common Stock Other $0 -827K -100% $0.00* 0 Feb 3, 2022 See footnote F1, F2
transaction RANI Class A Common Stock Other $0 +12.3K $0.00 12.3K Feb 3, 2022 See footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration.
F2 Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F3 VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person is a member of the general partner and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.